BRCA1 and ovarian cancer: 28.3% of recurrent ovarian cancer tumors contain secondary mutations as compared with only 3.1% in primary tumors, while 46.2% of platinum resistant tumors have secondary mutations that restored the function of BRCA1/2 as compared with 5.3% that are sensitive to platinum drugs (69).